Quarterly Result4 Aug 2026, 08:30 pm
Sanofi India Declares Q2 2026 Unaudited Financial Results
AI Summary
Sanofi India Limited announced its unaudited financial results for the quarter and half-year ended June 30, 2026. The company reported domestic net sales growth of 8% and total net sales growth of 6% for Q2 2026 compared to Q2 2025. The Insulin portfolio showed strong performance with 14% growth, driven by key products like Lantus®, Toujeo®, and Apidra®. Public sector business accelerated by 70%. Profits before tax and exceptional items increased by 19% to ₹112 crores. The Board also approved the re-constitution of the Stakeholders Relationship Committee and Risk Management Committee, and noted the stepping down of Mr. Rachid Ayari as Whole Time Director and CFO.
Key Highlights
- Unaudited financial results for Q2 and H1 ended June 30, 2026, were approved.
- Q2 2026 saw 8% domestic and 6% total net sales growth YoY.
- Insulin portfolio grew 14%, with strong performance in basal analog market.
- Profits before tax increased 19% to ₹112 crores in Q2 2026.
- Board approved committee re-constitutions and noted CFO stepping down.
Price Impact
More from SANOFI